Abstract
Introduction: The recent use of new direct-acting drugs (DAAs) in the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV coinfected patients. Case Presentation: Here, we report the case of a 47-year-old female patient with HBV/HCV coinfection who experienced HBV reactivation during treatment with daclatasvir (DCV) and sofosbuvir (SOF). In addition to the DAAs, Entecavir (ETV) was added to the combined regimen with improvement in ALT levels. Conclusions: Both HBV and HCV treatment could be implemented effectively in case of reactivation of HBV during anti-HCV treatment with DAAs. Close monitoring of HBV DNA and ALT levels are highly recommended during DAAs drug therapy for HCV in patients with HBV/HCV dual infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
